{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T07:28:37Z","timestamp":1787383717053,"version":"build-2736575974"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Macrophage activation syndrome (MAS) is a severe complication of autoimmune diseases with high mortality. We report the effectiveness of baricitinib as an option for the maintenance therapy in MAS secondary to nodular panniculitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case summary<\/jats:title><jats:p>A 24-year-old female came to our hospital with repeated fever and a skin nodule on right tibial tuberosity. Results were notable for raised serum ferritin (SF), triglycerides (TG), elevated liver function enzymes, interleukin-6 (IL-6), interferon-\u03b3 (IFN-\u03b3), soluble interleukin-2 receptor (sIL-2R) and decreased activity of NK cells. The pathological biopsy of the subcutaneous nodules indicated nodular panniculitis. Hemophagocytic cells were found in bone marrow aspiration. She was diagnosed as MAS secondary to nodular panniculitis. With the treatment of methylprednisolone (MP) and immunoglobulin, her symptoms and laboratory data gradually improved. Nevertheless, her disease relapsed when the MP dose was tapered. Regarding the usage of JAK inhibitors in MAS, we used baricitinib (JAK1\/2 inhibitor) to treat MAS and her symptom and abnormal laboratory findings returned to normal. During follow-up, though the MP dose was tapered, she was stable without a MAS recurrence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The case report suggested baricitinib is an option for MAS in the maintenance therapy phase and is potentially beneficial to prevent recurrence.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.914265","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T16:43:02Z","timestamp":1657125782000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Case Report: Baricitinib as an Alternative in the Maintenance Therapy for Macrophage Activation Syndrome Secondary to Nodular Panniculitis"],"prefix":"10.3389","volume":"13","author":[{"given":"Guanqun","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoling","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianwang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04722-y","article-title":"Analysis of the Clinical Characteristics of Thirteen Patients With Weber-Christian Panniculitis","volume":"38","author":"Zheng","year":"2019","journal-title":"Clin Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.246077","article-title":"Nodular Panniculitis With Hemophagocytic Lymphohistiocytosis","volume":"131","author":"Liu","year":"2018","journal-title":"Chin Med J (Engl)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/rheumatology\/key006","article-title":"Macrophage Activation Syndrome in Adults: Recent Advances in Pathophysiology, Diagnosis and Treatment","volume":"58","author":"Carter","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult Haemophagocytic Syndrome","volume":"383","author":"Ramos-Casals","year":"2014","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25063","article-title":"Ruxolitinib as First-Line Treatment in Secondary Hemophagocytic Lymphohistiocytosis: A Second Experience","volume":"93","author":"Zandvakili","year":"2018","journal-title":"Am J Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez284","article-title":"IL-18 as Therapeutic Target in a Patient With Resistant Systemic Juvenile Idiopathic Arthritis and Recurrent Macrophage Activation Syndrome","volume":"59","author":"Yasin","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s10067-013-2227-1","article-title":"Recurrent Macrophage Activation Syndrome as the Primary Manifestation in Systemic Lupus Erythematosus and the Benefit of Serial Ferritin Measurements: A Case-Based Review","volume":"32","author":"Vilaiyuk","year":"2013","journal-title":"Clin Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4081\/reumatismo.2019.1204","article-title":"Macrophage Activation Syndrome as a Complication of Rheumatologic Disorders, a Report From Iran","volume":"71","author":"Assari","year":"2020","journal-title":"Reumatismo"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM195010052431401","article-title":"Chronic Relapsing Febrile Nodular Nonsuppurative Panniculitis (Weber-Christian Disease); Relation to Rheumatic Fever and Allied Diseases","volume":"243","author":"Brudno","year":"1950","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and Therapeutic Guidelines for Hemophagocytic Lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/art.38690","article-title":"Development and Validation of the HScore, A Score for the Diagnosis of Reactive Hemophagocytic Syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30156-5","article-title":"Ruxolitinib in Adult Patients With Secondary Haemophagocytic Lymphohistiocytosis: An Open-Label, Single-Centre, Pilot Trial","volume":"6","author":"Ahmed","year":"2019","journal-title":"Lancet Haematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2020.1729405","article-title":"Tofacitinib-Induced Remission in Refractory Adult-Onset Still's Disease Complicated by Macrophage Activation Syndrome","volume":"49","author":"Honda","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-020-08786-6","article-title":"JAK Inhibitors: Prospects in Connective Tissue Diseases","volume":"59","author":"You","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199324060-00004","article-title":"Cyclosporin Clinical Pharmacokinetics","volume":"24","author":"Fahr","year":"1993","journal-title":"Clin Pharmacokinet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.914265\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T16:43:04Z","timestamp":1657125784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.914265\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":15,"alternative-id":["10.3389\/fimmu.2022.914265"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.914265","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,6]]},"article-number":"914265"}}